ID6 Cost-Effectiveness of Liposomal Daunorubicin Versus Liposomal Doxorubicin in Kaposi Sarcoma

@article{Egan1998ID6CO,
  title={ID6 Cost-Effectiveness of Liposomal Daunorubicin Versus Liposomal Doxorubicin in Kaposi Sarcoma},
  author={T Egan and Hugues Henry},
  journal={Value in Health},
  year={1998},
  volume={1},
  pages={39-39}
}
Kaposi sarcoma (KS) prior to 1980 was a rare indolent disorder seen in elderly men of Eastern European descent. Today it is the most common neoplasm seen in patients with AIDS and has been estimated to contribute to 25% of the deaths. Chemotherapy is the mainstay treatment of KS in patients with extensive or progressive disease involving the visceral organs and lymph nodes. Two agents, liposomal daunorubicin (Daunoxome®) and liposomal doxorubicin (Doxil®), have replaced treatment with the toxic… 
3 Citations
Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS–Kaposi’s sarcoma
TLDR
Paclitaxel is dominant in treating AIDS-KS due to its lower acquisition cost and high response rate and after accounting for all the factors that contribute to cost and response rate, paclitaxe is more cost effective than liposomal doxorubicin.
A review of the efficacy and outcomes studies of currently approved chemotherapy treatments for advanced AIDS-Kaposi's sarcoma
TLDR
This work compared studies of liposomal anthracyclines, still; further research among all the approved drugs for KS is warranted to evaluate efficacy as well as its economic burden worldwide.
Original research Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS-Kaposi's sarcoma
TLDR
This study aims to perform a cost-effectiveness analysis between liposomal doxorubicin and paclitaxel in treating AIDS-KS.